Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Exelon acquisition
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jun 10, 2021 12:23pm
150 Views
Post# 33362884

RE:RE:Re: Exelon acquisition

RE:RE:Re: Exelon acquisition
MrMugsy wrote:
curiousj wrote: considering the price paid for Exelon, do you think given the news from Biogen, that Knight paying 3.8x sales for the product was too much? Especially knowing that Novartis can still compete with Knight through Sandoz  


And ...

Demand may grow up to 10x by 2050

And ...

The potential to enter smaller geographies is certainly a GUD focus

And ...

GUD promotion will have a positive effect on sales growth

Oh ... and ...

future partnerships with Novartis are likely - new Exelon sales in ROW geographies may seal a bigger deal for other Novartis drugs.


Sorry Curious ... I just realized that you were asking a question ... while I was adding points to why there's likely success in this acquisition.  I think there is lots of room to compete with Sandoz and there are countries where we can likely take the lead.  Probably comes down to the ability of the sales/marketing teams.

Also, are there any other motives for buying the IP and handing it over to a 3rd Party?  We don't understand this well yet.  Maybe some hidden value here ???
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities